Jaguar Gene Therapy, a biotechnology firm based in Illinois, has been making significant strides in the development of gene therapies for severe genetic diseases, with a particular focus on conditions that affect large patient populations. Three years after its emergence from stealth mode, backed by Deerfield Management, the company has made headlines with the establishment of Advanced Medicine Partners. This spinout, supported by Deerfield, ARCH Venture Partners, and Nolan Capital, takes over the chemistry, manufacturing, and controls (CMC) responsibilities previously held by Jaguar. Advanced Medicine Partners aims to excel in the development of advanced medicines, including gene and cell therapies, by addressing the challenges of quality and scalability that have previously hampered the introduction of new treatments.
The collaboration between Jaguar Gene Therapy and Advanced Medicine Partners is a testament to their shared commitment to advancing healthcare. Advanced Medicine Partners, besides undertaking contract work, will spearhead the CMC efforts for Jaguar’s ongoing projects. These projects include promising treatments for genetic disorders like autism, Type 1 diabetes, and Type 1 galactosemia. To support these endeavors, Advanced Medicine Partners is constructing a 174,000-square-foot manufacturing facility in Durham, North Carolina. This facility is designed to augment their capacity for partner projects and is a direct result of Jaguar’s significant investment, following closely after their Series A and B funding rounds.
In a recent breakthrough, Jaguar Gene Therapy announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for JAG201. This gene therapy targets a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS), conditions for which there are currently no treatments available. JAG201 aims to deliver a functional SHANK3 gene directly into the central nervous system using the AAV9 vector, addressing the root cause of the disease. Preclinical studies have shown promising results, demonstrating improvements in neurobehavioral, cognitive, and motor functions. The company is planning to initiate Phase I clinical trials in the latter half of the year, marking a significant step forward in the treatment of these disorders.
The efforts of Jaguar Gene Therapy and its partners reflect a broader commitment to addressing unmet medical needs within the field of genetic disorders. The work on JAG201, in particular, offers hope to the approximately 30,000 individuals in the U.S. suffering from ASD or PMS related to SHANK3 mutations or deletions. Through collaborations with esteemed institutions and leveraging cutting-edge science, Jaguar Gene Therapy is poised to potentially transform the lives of patients and their families, offering them treatments that target the underlying causes of their conditions. As the company moves forward with its clinical trials, it stands on the forefront of a new era in gene therapy, bringing us closer to realizing the full potential of these groundbreaking treatments.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Rare diseases currently afflict 300 million people worldwide and 30 million people in the U.S. alone. However, 95% of these diseases lacked an FDA-approved treatment as of January 2023. One reason, industry leaders say, is cost. A 2019 study estimated that orphan drug...
SN Bioscience's pioneering nanoparticle anticancer drug, SNB-101, has sparked hope for patients battling various forms of cancer. Developed from the highly insoluble SN-38 into polymer nanoparticles, SNB-101 has exhibited significant improvements in efficacy and...
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
- Conducted in Collaboration with Columbia University, the CheMo4METPANC Phase 2 trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies compared to chemo alone - - Gulam Manji, MD,...
The success of mRNA vaccines against COVID-19 has unleashed a flood of interest in using the technology to create more vaccines and treatments for everything from rare diseases and infections to cancer. But before new mRNA therapeutics are put to use, they need to be...